Vanguard Group
MRVI icon

Vanguard Group’s Maravai LifeSciences MRVI Stock Holding History

Vanguard Group’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$23.3M Buy
7,166,528
+41,030
+0.6% +$138K ﹤0.01% 2546
2025
Q3 		$20.5M Sell
7,125,498
-2,255,049
-24% -$5.76M ﹤0.01% 2611
2025
Q2 		$22.6M Sell
9,380,547
-2,278,394
-20% -$4.79M ﹤0.01% 2502
2025
Q1 		$25.8M Sell
11,658,941
-162,483
-1% -$642K ﹤0.01% 2399
2024
Q4 		$64.4M Sell
11,821,424
-60,316
-0.5% -$388K ﹤0.01% 2058
2024
Q3 		$98.7M Buy
11,881,740
+1,133,130
+11% +$9.8M ﹤0.01% 1876
2024
Q2 		$77M Buy
10,748,610
+710,484
+7% +$6.13M ﹤0.01% 1959
2024
Q1 		$87M Buy
10,038,126
+34,232
+0.3% +$232K ﹤0.01% 1934
2023
Q4 		$65.5M Sell
10,003,894
-213,388
-2% -$1.38M ﹤0.01% 2075
2023
Q3 		$102M Sell
10,217,282
-341,685
-3% -$3.75M ﹤0.01% 1801
2023
Q2 		$131M Sell
10,558,967
-230
-0% -$3.1K ﹤0.01% 1704
2023
Q1 		$148M Buy
10,559,197
+169,218
+2% +$2.43M ﹤0.01% 1618
2022
Q4 		$149M Buy
10,389,979
+177,381
+2% +$2.79M ﹤0.01% 1596
2022
Q3 		$261M Sell
10,212,598
-220,435
-2% -$5.53M 0.01% 1224
2022
Q2 		$296M Sell
10,433,033
-79,184
-0.8% -$2.51M 0.01% 1181
2022
Q1 		$371M Sell
10,512,217
-21,392
-0.2% -$717K 0.01% 1165
2021
Q4 		$441M Buy
10,533,609
+426,670
+4% +$17.3M 0.01% 1081
2021
Q3 		$496M Buy
10,106,939
+1,758,189
+21% +$85.8M 0.01% 976
2021
Q2 		$348M Buy
8,348,750
+2,992,196
+56% +$116M 0.01% 1245
2021
Q1 		$191M Buy
5,356,554
+643,102
+14% +$21.3M 0.01% 1602
2020
Q4 		$132M Buy
+4,713,452
New +$131M ﹤0.01% 1695

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCM
Philosophy Capital Management Alamo, California $1.63B AUM 12.69% 1-Year Est. Return

Vanguard Group's MRVI Position: Q4 2025 in Review

Vanguard Group increased its Maravai LifeSciences (MRVI) stake by 0.58% in Q4 2025, buying an estimated $138K and bringing the position to 7,166,528 shares worth $23.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2546.

Vanguard Group first reported a position in MRVI in Q4 2020 and has held it in 21 quarters since. The position peaked at $496M in Q3 2021. 159 funds tracked by Wall St. Rank hold MRVI as of Q4 2025.

  • Vanguard Group held 7,166,528 shares of Maravai LifeSciences worth $23.3M as of Q4 2025.
  • Vanguard Group bought 41,030 Maravai LifeSciences shares in Q4 2025, an estimated $138K.
  • Maravai LifeSciences made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2546 holding.
  • Vanguard Group first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 21 quarters since.
  • Vanguard Group's Maravai LifeSciences position peaked at $496M in Q3 2021.
  • 159 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.